Core B – Medicinal and Process Chemistry

项目摘要-核心B 抗病毒对策开发中心（AC/DC）的药物化学核心（核心B）将是 由埃默里药物开发研究所（EIDD）和研究小组的联合能力组成 丹尼斯·廖塔教授的该核心将集中所有AC/DC化学操作，包括药物 化学，放大合成，工艺开发和预配制分析到一个高效的团队， 将减少围绕多个项目感兴趣的化学型的冗余研究。它也会与 与所有AC/DC项目和核心密切合作，以实现前所未有的协同和整合 整个中心。AC/DC将在其管道中拥有一套引人注目的线索，早期线索和经过验证的命中 在操作开始时的不同开发和优化阶段。这些化合物具有广泛的 一系列的化学型，将平行进行，包括广泛活性的核糖核苷铅，非- 核苷病毒聚合酶抑制剂先导和病毒蛋白酶抑制剂命中。新的经验证的命中出现在 核心F（HTS）也将通过迭代SAR优化来推进，以确保持续的强大管道， 处于不同发展阶段的候选药物。最后，核心B将开发规模扩大流程， 预配制配置文件，以支持在整个AC/DC中推进晚期电极导线。

Project Summary – Core B The Medicinal Chemistry Core (Core B) of the Antiviral Countermeasures Development Center (AC/DC) will be composed of the combined capacity of the Emory Institute for Drug Development (EIDD) and the research group of Professor Dennis Liotta. This Core will centralize all AC/DC chemistry operations including medicinal chemistry, scale-up synthesis, process development and preformulation profiling into a highly efficient team that will reduce redundant research around chemotypes that are of interest to multiple Projects. It will also interact closely with all AC/DC Projects and Cores to allow for an unprecedented level of synergy and integration throughout the Center. The AC/DC will have a compelling set of leads, early leads and validated hits in its pipeline at various stages of development and optimization at the onset of operations. These compounds present a wide array of chemotypes that will be pursued in parallel, including broadly active ribonucleoside leads, non- nucleoside viral polymerase inhibitor leads, and viral protease inhibitor hits. New validated hits emerging from Core F (HTS) will also be advanced through iterative SAR optimization to ensure an ongoing robust pipeline of drug candidates at various stages of development. Finally, Core B will develop scale-up processes and preformulation profiles to support the advancement of late leads throughout the AC/DC.